Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07517133 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia

Study acronym: ENERGIZEKids
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 4 to 5 Eligibility criteria expanded, about 23 words · Secondary endpoints: details revised at 3 of 28 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 3 of 28 entries
  2. Trial sites expanded: 1 → 4 locationsv5
  3. Recruitment opened Study sites: 0 to 1v4 Show 1 more changeShow less
    • Study sites: 0 to 1
  4. 2 versions Re-verified since May 28, 2026, no change to tracked fieldsv2-v3
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is to compare the effect of mitapivat versus placebo on anemia in pediatric participants with alpha- or beta-non-transfusion-dependent thalassemia.
Trial Details
NCT Number NCT07517133
Lead Sponsor Agios Pharmaceuticals, Inc.
Conditions Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov